Dergi makalesi Açık Erişim
Nayman, Ayse Hande; Siginc, Halime; Zemheri, Ebru; Yencilek, Faruk; Yildirim, Asif; Telci, Dilek
{ "conceptrecid": "69816", "created": "2021-03-16T03:07:14.231537+00:00", "doi": "10.7150/jca.29192", "files": [ { "bucket": "b473c04a-ed03-4c9c-b368-6c001cebb7d3", "checksum": "md5:950a0bd95d92b57c994b620f558d93b7", "key": "bib-5c465d76-6695-4ee9-9268-8d5e173d8c18.txt", "links": { "self": "https://aperta.ulakbim.gov.tr/api/files/b473c04a-ed03-4c9c-b368-6c001cebb7d3/bib-5c465d76-6695-4ee9-9268-8d5e173d8c18.txt" }, "size": 250, "type": "txt" } ], "id": 69817, "links": { "badge": "https://aperta.ulakbim.gov.tr/badge/doi/10.7150/jca.29192.svg", "bucket": "https://aperta.ulakbim.gov.tr/api/files/b473c04a-ed03-4c9c-b368-6c001cebb7d3", "doi": "https://doi.org/10.7150/jca.29192", "html": "https://aperta.ulakbim.gov.tr/record/69817", "latest": "https://aperta.ulakbim.gov.tr/api/records/69817", "latest_html": "https://aperta.ulakbim.gov.tr/record/69817" }, "metadata": { "access_right": "open", "access_right_category": "success", "communities": [ { "id": "tubitak-destekli-proje-yayinlari" } ], "creators": [ { "affiliation": "Yeditepe Univ, Fac Engn, Dept Genet & Bioengn, Kayisdagi Cad, TR-34755 Istanbul, Turkey", "name": "Nayman, Ayse Hande" }, { "affiliation": "Yeditepe Univ, Fac Engn, Dept Genet & Bioengn, Kayisdagi Cad, TR-34755 Istanbul, Turkey", "name": "Siginc, Halime" }, { "affiliation": "Umraniye Training & Res Hosp, Dept Pathol, Istanbul, Turkey", "name": "Zemheri, Ebru" }, { "affiliation": "Yeditepe Univ, Fac Sch Med, Yeditepe Univ Hosp, Istanbul, Turkey", "name": "Yencilek, Faruk" }, { "affiliation": "Medeniyet Univ, Fac Med, Dept Urol, Istanbul, Turkey", "name": "Yildirim, Asif" }, { "affiliation": "Yeditepe Univ, Fac Engn, Dept Genet & Bioengn, Kayisdagi Cad, TR-34755 Istanbul, Turkey", "name": "Telci, Dilek" } ], "description": "Renal cell carcinoma (RCC) is the predominant type of kidney cancer. Mammalian target of rapamycin (mTOR) inhibitor everolimus is currently used as a second-line therapy for sorafenib or sunitinib-refractory metastatic RCC patients. The clinical limitation confronted during everolimus therapy is the onset of drug resistance that decreases the efficacy of the drug. Elevated level of anti-apoptotic Bcl-2 protein is proposed to be an emerging feedback loop for the acquired drug-resistance in various cancer types. In this study, the Bcl-2 inhibitor ABT-737 was used in combination with everolimus to enhance its anti-tumor effectiveness in everolimus-resistant RCC cell lines. Everolimus and ABT-737 combination synergistically led to a decrease in the proliferation of primary site A-498 and metastatic site Caki-1 RCC cell lines, which was accompanied by a reduction in protein levels of cell cycle and mTOR pathway proteins. In both RCC cell lines, everolimus-ABT-737 combination not only induced apoptosis, caspase and PARP-1 cleavage but also a decrease in Bcl-2 protein levels in parallel with a concomitant increase in Bim and Noxa levels.", "doi": "10.7150/jca.29192", "has_grant": false, "journal": { "issue": "6", "pages": "1466-1478", "title": "JOURNAL OF CANCER", "volume": "10" }, "license": { "id": "cc-by" }, "publication_date": "2019-01-01", "relations": { "version": [ { "count": 1, "index": 0, "is_last": true, "last_child": { "pid_type": "recid", "pid_value": "69817" }, "parent": { "pid_type": "recid", "pid_value": "69816" } } ] }, "resource_type": { "subtype": "article", "title": "Dergi makalesi", "type": "publication" }, "title": "Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo" }, "owners": [ 1 ], "revision": 1, "stats": { "downloads": 7.0, "unique_downloads": 7.0, "unique_views": 50.0, "version_downloads": 7.0, "version_unique_downloads": 7.0, "version_unique_views": 50.0, "version_views": 54.0, "version_volume": 1750.0, "views": 54.0, "volume": 1750.0 }, "updated": "2021-03-16T03:07:14.280521+00:00" }
Görüntülenme | 54 |
İndirme | 7 |
Veri hacmi | 1.8 kB |
Tekil görüntülenme | 50 |
Tekil indirme | 7 |